US5554367A
(en)
*
|
1984-10-31 |
1996-09-10 |
Alcon Laboratories, Inc. |
Compositions for treatment of glaucoma
|
US5093126A
(en)
*
|
1987-09-26 |
1992-03-03 |
Alcon Laboratories, Inc. |
Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
|
US5188826A
(en)
*
|
1988-02-08 |
1993-02-23 |
Insite Vision Incorporated |
Topical ophthalmic suspensions
|
US5192535A
(en)
*
|
1988-02-08 |
1993-03-09 |
Insite Vision Incorporated |
Ophthalmic suspensions
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5660851A
(en)
*
|
1989-12-26 |
1997-08-26 |
Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem |
Ocular inserts
|
US5496471A
(en)
*
|
1990-01-08 |
1996-03-05 |
Ciba-Geigy Corporation |
Apparatus for removing components from solutions
|
US5124154A
(en)
*
|
1990-06-12 |
1992-06-23 |
Insite Vision Incorporated |
Aminosteroids for ophthalmic use
|
US5833665A
(en)
|
1990-06-14 |
1998-11-10 |
Integra Lifesciences I, Ltd. |
Polyurethane-biopolymer composite
|
US5252318A
(en)
*
|
1990-06-15 |
1993-10-12 |
Allergan, Inc. |
Reversible gelation compositions and methods of use
|
US5275820A
(en)
*
|
1990-12-27 |
1994-01-04 |
Allergan, Inc. |
Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
|
JP2536806B2
(ja)
*
|
1991-03-27 |
1996-09-25 |
アルコン ラボラトリーズ インコーポレイテッド |
ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
|
US5212162A
(en)
*
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
US5182102A
(en)
*
|
1991-07-12 |
1993-01-26 |
Alcon Laboratories, Inc. |
Anti-glaucoma compositions
|
US5320839A
(en)
*
|
1991-10-11 |
1994-06-14 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
|
CA2120603A1
(en)
*
|
1991-10-11 |
1993-04-15 |
Louis Desantis Jr. |
Topical opthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
|
JP2873530B2
(ja)
*
|
1991-12-13 |
1999-03-24 |
参天製薬株式会社 |
ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
DE69320329T2
(de)
*
|
1992-02-21 |
1998-12-24 |
Alcon Lab Inc |
Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
|
US5296228A
(en)
*
|
1992-03-13 |
1994-03-22 |
Allergan, Inc. |
Compositions for controlled delivery of pharmaceutical compounds
|
TW205503B
(en)
*
|
1992-04-24 |
1993-05-11 |
Ciba Geigy Ag |
Apparatus for removing components from solutions
|
WO1993023082A1
(en)
*
|
1992-05-13 |
1993-11-25 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
|
US5520920A
(en)
*
|
1992-08-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
|
AU666957B2
(en)
|
1992-08-28 |
1996-02-29 |
Alcon Laboratories, Inc. |
Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
|
ES2105333T3
(es)
*
|
1992-10-13 |
1997-10-16 |
Alcon Lab Inc |
Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
|
US5340572A
(en)
*
|
1993-02-08 |
1994-08-23 |
Insite Vision Incorporated |
Alkaline ophthalmic suspensions
|
EP0664699A1
(de)
*
|
1993-08-13 |
1995-08-02 |
Vitaphore Corporation |
Arzneimittelabgabesystem auf der Basis von Hydrogelmikrokugeln
|
JP2742333B2
(ja)
*
|
1994-05-06 |
1998-04-22 |
アルコン ラボラトリーズ,インコーポレイテッド |
眼科用組成物におけるビタミンeトコフェリル誘導体の使用
|
US5662919A
(en)
*
|
1994-11-21 |
1997-09-02 |
Alcon Laboratories, Inc. |
Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds
|
US5612027A
(en)
*
|
1995-04-18 |
1997-03-18 |
Galin; Miles A. |
Controlled release of miotic and mydriatic drugs in the anterior chamber
|
US5972326A
(en)
*
|
1995-04-18 |
1999-10-26 |
Galin; Miles A. |
Controlled release of pharmaceuticals in the anterior chamber of the eye
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
EP1057486A1
(de)
*
|
1995-11-17 |
2000-12-06 |
Alcon Laboratories, Inc. |
Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
CN1155383C
(zh)
|
1995-12-21 |
2004-06-30 |
阿尔康实验室公司 |
某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途
|
US6159458A
(en)
*
|
1997-11-04 |
2000-12-12 |
Insite Vision |
Sustained release ophthalmic compositions containing water soluble medicaments
|
US6486208B1
(en)
|
1998-09-25 |
2002-11-26 |
Alcon Laboratories, Inc. |
Sustained release, and comfortable opthalmic composition and method for ocular therapy
|
EP1124535B1
(de)
|
1998-10-27 |
2002-12-11 |
Alcon Laboratories, Inc. |
Konservierungsmittel für lokale pharmazeutische zubereitungen enthaltend eine fettsäure/aminosäure enthaltende seife
|
US6444710B1
(en)
|
1998-10-27 |
2002-09-03 |
Alcon Manufacturing, Ltd. |
Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
|
US6146622A
(en)
*
|
1998-10-27 |
2000-11-14 |
Alcon Laboratories, Inc. |
Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
|
JP2002528423A
(ja)
|
1998-10-27 |
2002-09-03 |
アルコン ラボラトリーズ, インコーポレイテッド |
局所投与可能な薬学的組成物のための保存系
|
US6258350B1
(en)
|
1999-01-20 |
2001-07-10 |
Alcon Manufacturing, Ltd. |
Sustained release ophthalmic formulation
|
NZ513164A
(en)
|
1999-01-25 |
2006-03-31 |
Nat Jewish Med & Res Center |
Substituted porphyrins
|
AU4338700A
(en)
*
|
1999-05-12 |
2000-12-05 |
Alcon Laboratories, Inc. |
Use of polymeric adsorbents in pharmaceutical dosage forms
|
US6730691B1
(en)
|
2000-02-10 |
2004-05-04 |
Miles A. Galin |
Uses of alpha adrenergic blocking agents
|
DE10115282B4
(de)
*
|
2000-03-29 |
2006-03-02 |
Hitachi, Ltd. |
Einlaßluftsteuervorrichtung und Brennkraftmaschine, in der sie montiert ist
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US20020176842A1
(en)
*
|
2001-04-09 |
2002-11-28 |
Lyn Hughes |
Extended release of active ingredients
|
EP1439842A4
(de)
*
|
2001-06-01 |
2009-09-02 |
Nat Jewish Med & Res Center |
Oxidantienfänger zur behandlung von diabetes oder zur verwendung bei der transplantation oder induktion von immuntoleranz
|
US6743439B1
(en)
|
2001-06-27 |
2004-06-01 |
Alcon, Inc. |
Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
|
US20030100594A1
(en)
*
|
2001-08-10 |
2003-05-29 |
Pharmacia Corporation |
Carbonic anhydrase inhibitor
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
EP1429728A1
(de)
*
|
2001-08-29 |
2004-06-23 |
SRL Technologies, Inc. |
Zubereitungen mit verzögerter freisetzung
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
WO2003039454A2
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
US7001615B1
(en)
|
2001-12-07 |
2006-02-21 |
Alcon, Inc. |
Sustained release ophthalmic, otic and nasal suspension
|
CN1671400A
(zh)
*
|
2002-07-03 |
2005-09-21 |
派瑞克科学公司 |
透明质酸组合物以及使用方法
|
US20050147584A1
(en)
*
|
2004-01-05 |
2005-07-07 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20050031652A1
(en)
*
|
2003-02-25 |
2005-02-10 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20050277698A1
(en)
*
|
2004-01-05 |
2005-12-15 |
Hughes Patrick M |
Memantine delivery to the back of the eye
|
US20050265955A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Mallinckrodt Inc. |
Sustained release preparations
|
AU2005286774A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
CA2580238A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc. |
Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
|
US20060111388A1
(en)
*
|
2004-11-19 |
2006-05-25 |
University Of North Texas Health Science Center At Fort Worth |
Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
|
JP2008520744A
(ja)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
JP2008535863A
(ja)
*
|
2005-04-08 |
2008-09-04 |
コメンティス,インコーポレーテッド |
β−セクレターゼ活性を阻害する化合物およびその使用方法
|
US20070077302A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Azaam Alli |
Methods for stabilizing ophthalmic compositions
|
EP1957986B1
(de)
*
|
2005-11-22 |
2017-05-24 |
McGill University |
Frühgene mit reguliertem zwischenaugendruck und verwendungen davon
|
WO2008005457A2
(en)
|
2006-06-30 |
2008-01-10 |
Sunesis Pharmaceuticals |
Pyridinonyl pdk1 inhibitors
|
US8158667B2
(en)
*
|
2006-08-21 |
2012-04-17 |
Kador Peter F |
Topical treatment of cataracts in dogs
|
CA2671613C
(en)
*
|
2006-12-05 |
2018-07-03 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Methods of use of trk receptor modulators
|
AU2011253937B2
(en)
*
|
2006-12-05 |
2012-09-27 |
The Royal Institution For The Advancement Of Learning/ Mcgill University |
Methods of use of TRK receptor modulators
|
US8968786B2
(en)
|
2007-06-22 |
2015-03-03 |
Board Of Regents, The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
EP2178837A2
(de)
*
|
2007-07-26 |
2010-04-28 |
Comentis, Inc. |
Isophthalamidderivate als hemmer der beta-sekretase-aktivität
|
MX2010002938A
(es)
*
|
2007-09-24 |
2010-04-01 |
Comentis Inc |
Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
|
EP2300003B1
(de)
|
2008-05-23 |
2014-03-05 |
National Jewish Health |
Verbindungen zur Verwendung bei der Behandlung von Verletzungen aufgrund der Exposition zu einer alkylierenden Spezies
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
WO2010011684A2
(en)
*
|
2008-07-21 |
2010-01-28 |
The Regents Of The University Of California |
Prodrug and fluoregenic compositions and methods for using the same
|
CN102264728B
(zh)
|
2008-09-15 |
2015-02-04 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
JP2012516187A
(ja)
*
|
2009-02-20 |
2012-07-19 |
マイクロ ラブズ リミテッド |
貯蔵安定性プロスタグランジン製品
|
ES2817700T3
(es)
|
2009-08-17 |
2021-04-07 |
Memorial Sloan Kettering Cancer Center |
Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
|
US8785440B2
(en)
|
2009-09-04 |
2014-07-22 |
Biogen Idec Ma, Inc. |
Bruton's tyrosine kinase inhibitors
|
US9029359B2
(en)
|
2009-09-04 |
2015-05-12 |
Biogen Idec Ma, Inc. |
Heteroaryl Btk inhibitors
|
PT2485731T
(pt)
|
2009-10-06 |
2016-08-17 |
Millennium Pharm Inc |
Compostos heterocíclicos úteis como inibidores de pdk1
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
PT2853262T
(pt)
|
2009-10-26 |
2017-01-31 |
Sephoris Pharmaceuticals Llc |
Tratamento de queimaduras solares usando analgésicos e anti-histamínicos
|
US20130035325A1
(en)
|
2009-11-16 |
2013-02-07 |
The Regents Of The University Of California |
Kinase inhibitors
|
KR102079160B1
(ko)
|
2009-12-10 |
2020-02-19 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
아밀로이드 결합제
|
BR112012024678A2
(pt)
|
2010-03-30 |
2016-06-07 |
Verseon Corp |
composto, composição farmacêutica, e, métodos para tratar e para previnir uma doença ou distúrbio
|
WO2012058645A1
(en)
|
2010-10-29 |
2012-05-03 |
Biogen Idec Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
KR101935068B1
(ko)
|
2011-02-14 |
2019-01-03 |
알러간, 인코포레이티드 |
비마토프로스트 조성물의 에스테르 유도체 및 방법
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
WO2012158843A2
(en)
|
2011-05-17 |
2012-11-22 |
The Regents Of The University Of California |
Kinase inhibitors
|
WO2012158764A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
EP2714069A4
(de)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
Langzeitkonjugate mit zwei hormonen
|
JP6109165B2
(ja)
|
2011-07-01 |
2017-04-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ヘルペスウイルスワクチンおよび使用方法
|
JP6342805B2
(ja)
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
置換ピラゾロ[3,4−d]ピリミジンおよびその用途
|
US9073851B2
(en)
|
2011-10-28 |
2015-07-07 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer
|
JP6399660B2
(ja)
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
癌治療用組成物および方法
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
WO2013185082A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Inhibitors of bruton's tyrosine kinase
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
CN104684904B
(zh)
|
2012-08-27 |
2017-10-13 |
阿勒根公司 |
通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
|
DK3181567T3
(da)
|
2012-09-10 |
2019-06-11 |
Principia Biopharma Inc |
Pyrazolopyrimidinforbindelser som kinasehæmmere
|
AU2013323426A1
(en)
|
2012-09-26 |
2015-04-23 |
The Regents Of The University Of California |
Modulation of ire1
|
CN108440571B
(zh)
|
2012-10-22 |
2022-11-04 |
希望之城 |
Etp衍生物
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
CA2900779C
(en)
|
2013-02-11 |
2021-10-26 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
WO2014165263A1
(en)
|
2013-03-12 |
2014-10-09 |
The Regents Of The University Of California, A California Corporation |
Gamma-secretase modulators
|
US9321745B2
(en)
|
2013-03-12 |
2016-04-26 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid IP receptors
|
US9295665B2
(en)
|
2013-03-12 |
2016-03-29 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
|
EA035877B1
(ru)
|
2013-03-14 |
2020-08-25 |
Сити Оф Хоуп |
Оксим-замещенные 5-бром-индирубины
|
EP2968270A4
(de)
|
2013-03-14 |
2016-08-17 |
Univ California |
Modulation von k2p-kanälen
|
JP6594853B2
(ja)
|
2013-03-14 |
2019-10-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
チオ糖粘液溶解薬
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
JP6806562B2
(ja)
|
2013-03-15 |
2021-01-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
eIF2α経路の調節因子
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
CN110101699A
(zh)
|
2013-03-15 |
2019-08-09 |
维颂公司 |
作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
|
CA2901529A1
(en)
|
2013-03-15 |
2014-09-18 |
Allergan, Inc. |
Bimatoprost for enhancement of leptin production
|
SG11201506757TA
(en)
|
2013-03-15 |
2015-09-29 |
Verseon Corp |
Halogenopyrazoles as inhibitors of thrombin
|
EP2970346B1
(de)
|
2013-03-15 |
2018-08-08 |
The Regents of the University of California |
Acyclische nukleosidphosphonatdiester
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
CA2949048A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
WO2015009742A2
(en)
|
2013-07-15 |
2015-01-22 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
EP3035926B1
(de)
|
2013-08-19 |
2020-07-29 |
The Regents of The University of California |
Verbindungen und verfahren zur behandlung einer epileptischen erkrankung
|
CN105979941A
(zh)
|
2013-08-20 |
2016-09-28 |
希望之城 |
用于治疗癌症的hdac8抑制剂
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
WO2015089327A1
(en)
|
2013-12-11 |
2015-06-18 |
Biogen Idec Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
HUE040346T2
(hu)
|
2013-12-11 |
2019-03-28 |
Biogen Ma Inc |
Az onkológia, neurológia és immunológia területén a humán betegségek kezelésében hasznos biaril vegyületek
|
RU2016128528A
(ru)
|
2013-12-23 |
2018-01-30 |
Мемориал Слоун-Кеттеринг Кэнсэ Сентр |
Способы и реактивы для введения радиоактивной метки
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
CA2939219C
(en)
|
2014-02-11 |
2023-02-28 |
Mitokinin Llc |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
EP3104857A4
(de)
|
2014-02-14 |
2017-10-11 |
The Regents of The University of California |
Cyclische peroxyde als prodrugs zur selektiven abgabe von wirkstoffen
|
DK3107906T3
(en)
|
2014-02-20 |
2019-03-18 |
Allergan Inc |
REDUCED CENTRAL CORNER MAP THICKNESS USING HYDROFILE ESTER PRODRUGS OF BETA-CHLORCYCLOPENTANE
|
SG11201606858RA
(en)
|
2014-02-21 |
2016-09-29 |
Principia Biopharma Inc |
Salts and solid form of a btk inhibitor
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
WO2015148839A1
(en)
|
2014-03-26 |
2015-10-01 |
City Of Hope |
Treatment of brca1-defective cancer or resistant cancers
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
CA2948621A1
(en)
|
2014-05-13 |
2015-11-19 |
Memorial Sloan Kettering Cancer Center |
Hsp70 modulators and methods for making and using the same
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
EP3179982B1
(de)
|
2014-07-28 |
2023-07-19 |
Sun Pharma Advanced Research Company Ltd |
Verfahren zur erhöhung der bioverfügbarkeit und/oder zur verlängerung der ophthalmischen wirkung eines arzneimittels
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
CN113620978A
(zh)
|
2014-09-11 |
2021-11-09 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
HUE059067T2
(hu)
|
2014-09-15 |
2022-10-28 |
Univ California |
Nukleotid analógok
|
EP3194369A4
(de)
|
2014-09-17 |
2018-02-28 |
Verseon Corporation |
Pyrazolylsubstituierte pyridonverbindungen als serinproteaseinhibitoren
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
EP3197870B1
(de)
|
2014-09-25 |
2020-08-19 |
Araxes Pharma LLC |
Inhibitoren von g12c mutierten kras proteinen
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
WO2016054596A1
(en)
|
2014-10-02 |
2016-04-07 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
SG11201704869VA
(en)
|
2014-12-15 |
2017-07-28 |
Univ Johns Hopkins |
Sunitinib formulations and methods for use thereof in treatment of ocular disorders
|
ES2843323T3
(es)
|
2014-12-18 |
2021-07-16 |
Principia Biopharma Inc |
Tratamiento de pénfigo
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
AU2016206475B2
(en)
|
2015-01-16 |
2021-11-04 |
City Of Hope |
Cell penetrating antibodies
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
HUE059559T2
(hu)
|
2015-02-25 |
2022-12-28 |
Univ California |
5HT agonisták az epilepsziás rendellenességek kezelésére
|
WO2016138479A1
(en)
|
2015-02-27 |
2016-09-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
JP2018508513A
(ja)
|
2015-02-27 |
2018-03-29 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
軟骨若返りを可能とする小分子
|
LT3261639T
(lt)
|
2015-02-27 |
2022-11-25 |
Verseon International Corporation |
Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai
|
EP3277712A4
(de)
|
2015-03-30 |
2018-09-26 |
City of Hope |
Mechanisch ineinandergreifende komplexe
|
CA2981530A1
(en)
|
2015-04-10 |
2016-10-13 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
AU2016247858B2
(en)
|
2015-04-17 |
2020-10-15 |
Ludwig Institute For Cancer Research Ltd. |
PLK4 inhibitors
|
CN107709359A
(zh)
|
2015-04-24 |
2018-02-16 |
加利福尼亚大学董事会 |
Ror1‑ror2结合的调节剂
|
EP3842448A1
(de)
|
2015-05-15 |
2021-06-30 |
City of Hope |
Chimäre antigenrezeptorzusammensetzungen
|
BR112017024804B1
(pt)
*
|
2015-05-21 |
2024-02-27 |
Ophtalmis Monaco |
Composição oftálmica na forma de uma emulsão óleo-em-água, processo para preparar a emulsão óleo-em-água, e uso de ácido lipóico
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
WO2016201169A1
(en)
|
2015-06-10 |
2016-12-15 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
MA42510A
(fr)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
|
EP3313839A1
(de)
|
2015-06-24 |
2018-05-02 |
Principia Biopharma Inc. |
Tyrosin-kinase-inhibitoren
|
US10758624B2
(en)
|
2015-07-02 |
2020-09-01 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
JP7104462B2
(ja)
|
2015-08-06 |
2022-07-21 |
シティ・オブ・ホープ |
細胞透過性タンパク質-抗体コンジュゲートおよび使用方法
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
EP3350181B1
(de)
|
2015-09-02 |
2023-11-01 |
The Regents of The University of California |
Her3-liganden und ihre verwendungen
|
JP6933644B2
(ja)
|
2015-09-04 |
2021-09-08 |
シティ・オブ・ホープCity of Hope |
アンドロゲン受容体拮抗薬
|
WO2017051251A1
(en)
|
2015-09-25 |
2017-03-30 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
EP3356351A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3356347A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356349A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3356353A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356359B1
(de)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3985116A1
(de)
|
2015-10-15 |
2022-04-20 |
City of Hope |
Verbindungen und zusammensetzungen mit phosphorthioiertem oligodesoxynukleotid und verfahren zur verwendung davon
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
US10662218B2
(en)
|
2015-10-23 |
2020-05-26 |
Erx Pharmaceuticals, Inc. |
Analogs of celastrol
|
EP3364971B1
(de)
|
2015-10-23 |
2020-06-17 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclische pdk1-inhibitoren zur verwendung zur behandlung von krebs
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
CN108367079B
(zh)
|
2015-11-12 |
2022-11-22 |
灰色视觉公司 |
用于治疗的聚集性微粒
|
TW201726656A
(zh)
|
2015-11-16 |
2017-08-01 |
亞瑞克西斯製藥公司 |
包含經取代雜環基團之2-經取代喹唑啉化合物及其使用方法
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
EP3386549A4
(de)
|
2015-12-10 |
2019-08-07 |
City of Hope |
Zellenpenetrierende cyaningekoppelte antikörper
|
IL260208B1
(en)
|
2015-12-24 |
2023-12-01 |
Univ California |
CFTR regulators and methods of using them
|
EP3394046B1
(de)
|
2015-12-24 |
2022-03-09 |
The Regents Of The University Of California |
Cftr-regulatoren und verfahren zur verwendung davon
|
WO2017120198A1
(en)
|
2016-01-05 |
2017-07-13 |
The Regents Of The University Of California |
Benzothiazole amphiphiles
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
US11208411B2
(en)
|
2016-03-17 |
2021-12-28 |
The Regents Of The University Of California |
Compositions and methods for treating parasitic diseases
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
WO2017189613A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
EP3448519A4
(de)
|
2016-04-29 |
2020-01-22 |
Board Of Regents, The University Of Texas System |
Sigma-rezeptor-bindemittel
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
CR20180502A
(es)
|
2016-05-12 |
2018-12-21 |
Anacor Pharmaceuticals Inc |
Ésteres de oxaborol y sus usos
|
CA3063834A1
(en)
|
2016-05-26 |
2017-11-30 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
CA3028169A1
(en)
|
2016-06-29 |
2018-01-04 |
Principia Biopharma Inc. |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
EP3487852A1
(de)
|
2016-07-21 |
2019-05-29 |
Biogen MA Inc. |
Succinatformen und zusammensetzungen von hemmern der bruton-tyrosinkinase
|
CN109789146B
(zh)
|
2016-07-29 |
2023-04-18 |
拉普特医疗公司 |
趋化因子受体调节剂及其用途
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
US20190218261A1
(en)
|
2016-09-13 |
2019-07-18 |
The Jackson Laboratory |
Targeted enhanced dna demethylation
|
CA3036852A1
(en)
|
2016-09-15 |
2018-03-22 |
City Of Hope |
Dithio etp derivatives
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
MX2019007030A
(es)
|
2016-12-15 |
2020-01-15 |
Univ California |
Composiciones y metodos para el tratamiento del cancer.
|
EP3573967A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Kondensierte bicyclische hetero-hetero-verbindungen und verfahren zur verwendung davon
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
WO2018175922A1
(en)
|
2017-03-23 |
2018-09-27 |
Graybug Vision, Inc. |
Drugs and compositions for the treatment of ocular disorders
|
RU2019139817A
(ru)
|
2017-05-10 |
2021-06-10 |
Грейбуг Вижн, Инк. |
Микрочастицы с замедленным высвобождением и их суспензии для лекарственной терапии
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
US11414419B2
(en)
|
2017-06-21 |
2022-08-16 |
Mitokinin, Inc. |
Substituted purines for the treatment of neurodegenerative and mitochondrial diseases
|
US11554178B2
(en)
|
2017-06-30 |
2023-01-17 |
City Of Hope |
Compositions and methods of modulating macrophage activity
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
EP3688028A2
(de)
|
2017-09-29 |
2020-08-05 |
Genentech, Inc. |
Antibiotische peptidkomplexe und verfahren zu deren verwendung
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
CA3078942A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazine compounds and methods of inhibiting tam kinases
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
US20200361881A1
(en)
|
2017-11-02 |
2020-11-19 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
IL274367B2
(en)
|
2017-11-02 |
2023-10-01 |
Calico Life Sciences Llc |
Combined pressure pathway modulators
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
MX2020004519A
(es)
|
2017-11-02 |
2020-11-09 |
Calico Life Sciences Llc |
Moduladores de la vía de estrés integrada.
|
JP2021501781A
(ja)
|
2017-11-02 |
2021-01-21 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
WO2019090088A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
CA3080948A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
CA3081750A1
(en)
|
2017-11-06 |
2019-05-09 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
DK3720438T3
(da)
|
2017-12-07 |
2023-10-02 |
Amplyx Pharmaceuticals Inc |
Svampedræbende midler, der er afledt af heterocyklus-substitueret pyridin
|
US11939575B2
(en)
|
2017-12-19 |
2024-03-26 |
City Of Hope |
Modified tracrRNAs gRNAs, and uses thereof
|
CA3088529A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US11311542B2
(en)
|
2018-01-16 |
2022-04-26 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin dependent kinase 7 (CDK7)
|
IL276295B2
(en)
|
2018-01-26 |
2024-02-01 |
Rapt Therapeutics Inc |
Modulators of chemokine receptors and their uses
|
JP2021517893A
(ja)
|
2018-03-13 |
2021-07-29 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
|
AU2019260793B2
(en)
|
2018-04-27 |
2023-05-18 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
IL300091A
(en)
|
2018-05-01 |
2023-03-01 |
Revolution Medicines Inc |
C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
|
AU2019262979B2
(en)
|
2018-05-01 |
2023-07-06 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mTOR inhibitors
|
WO2019213611A1
(en)
|
2018-05-04 |
2019-11-07 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
CR20210017A
(es)
|
2018-06-21 |
2021-11-03 |
Calico Life Sciences Llc |
Inhibidores de proteína tirosina fosfatosa y sus métodos de uso
|
US11771688B2
(en)
|
2018-06-25 |
2023-10-03 |
Amplyx Pharmaceuticals, Inc. |
Pyridine derivatives substituted by heterocyclic ring and amino group
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
EP3856742A4
(de)
|
2018-11-01 |
2022-06-22 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclische janus-kinase-1-inhibitoren und zusammensetzungen und verfahren dafür
|
WO2020186199A1
(en)
|
2019-03-14 |
2020-09-17 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
CN114206848A
(zh)
|
2019-04-30 |
2022-03-18 |
卡里科生命科学有限责任公司 |
作为整合应激通路的调节剂的被取代的环烷基化合物
|
CA3140046A1
(en)
|
2019-05-15 |
2020-11-19 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
US11787796B2
(en)
|
2019-09-18 |
2023-10-17 |
Takeda Pharmaceutical Company Limited |
Plasma Kallikrein inhibitors and uses thereof
|
BR112022004475A2
(pt)
|
2019-09-18 |
2022-05-31 |
Novartis Ag |
Proteínas de fusão nkg2d e usos das mesmas
|
CN114667289A
(zh)
|
2019-09-18 |
2022-06-24 |
武田药品工业有限公司 |
杂芳基血浆激肽释放酶抑制剂
|
WO2021097339A1
(en)
|
2019-11-13 |
2021-05-20 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
CN116348455A
(zh)
|
2019-12-18 |
2023-06-27 |
卡里科生命科学有限责任公司 |
蛋白质酪氨酸磷酸酶抑制剂和其使用方法
|
AU2021276656A1
(en)
|
2020-05-19 |
2022-11-24 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
KR20230053611A
(ko)
|
2020-08-18 |
2023-04-21 |
사이빈 아이알엘 리미티드 |
펜에틸아민 유도체, 조성물, 및 사용 방법
|
EP4237421A1
(de)
|
2020-11-02 |
2023-09-06 |
Trethera Corporation |
Kristalline formen eines desoxycytidinkinasehemmers und verwendungen davon
|
EP4247340A1
(de)
|
2020-11-18 |
2023-09-27 |
Bexson Biomedical, Inc. |
Komplexbildnersalzformulierungen von pharmazeutischen verbindungen
|
WO2022133237A2
(en)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
CA3208243A1
(en)
|
2021-03-17 |
2022-09-22 |
Nikolaos PAPAIOANNOU |
Heteroaryl inhibitors of plasma kallikrein
|
JP2024510504A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレインの多環式インヒビター
|
JP2024512497A
(ja)
|
2021-03-17 |
2024-03-19 |
武田薬品工業株式会社 |
血漿カリクレインの阻害剤
|
JP2024510503A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレイン阻害剤
|
EP4308227A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Imidazopyridinylhemmer von plasmakallikrein
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|